[Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models].
To explore the possibility of using lymphokine activated killer (LAK) from cord blood as an adoptive immunotherapy for ovarian cancer. The nude mouse models with human ovarian cancer were treated with the LAK from cord blood and compared with those treated with the LAK from the pheripheral blood. The LAK from the cord blood inhibited the growth of human ovarian cancer. The average size of the tumor was 6.0 mm3 23 days after the cord blood LAK treatment, with an average weight of (0.674 +/- 0.45 g). Cord blood can be a source of adoptive cellular immunotherapy for the treatment of ovarian cancer.